Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
CRSP | 49.19% | $3.39B | -38.23% | 0.00% |
OPEN | 48.35% | $1.05B | -58.12% | 0.00% |
ACLX | 48.02% | $3.74B | +24.33% | 0.00% |
ARVN | 47.77% | $1.28B | -51.91% | 0.00% |
RVMD | 47.49% | $7.62B | +46.60% | 0.00% |
ATXS | 47.24% | $420.43M | +6.58% | 0.00% |
RCKT | 46.15% | $1.18B | -61.06% | 0.00% |
SNDX | 45.52% | $1.12B | -41.05% | 0.00% |
NOVT | 45.44% | $5.30B | -5.27% | 0.00% |
PLRX | 44.54% | $730.85M | -32.91% | 0.00% |
RYTM | 44.42% | $3.45B | +38.08% | 0.00% |
BEAM | 43.66% | $2.19B | +3.09% | 0.00% |
RXRX | 43.51% | $2.69B | -38.35% | 0.00% |
CRNX | 43.10% | $3.76B | +9.14% | 0.00% |
CLDX | 43.01% | $1.62B | -42.08% | 0.00% |
PHR | 42.84% | $1.55B | +10.48% | 0.00% |
BN | 42.84% | $82.83B | +40.15% | 0.59% |
NRIX | 42.21% | $1.29B | +94.66% | 0.00% |
IDYA | 42.12% | $2.08B | -39.53% | 0.00% |
KN | 41.86% | $1.71B | +15.10% | 0.00% |
Current Value
$37.611 Year Return
Current Value
$37.611 Year Return
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
NAT | 0.06% | $603.42M | -35.20% | 13.61% |
INSW | -0.08% | $2.00B | -11.16% | 1.14% |
BF.A | -0.09% | $15.91B | -41.99% | 2.62% |
FATBB | 0.10% | $88.50M | -7.04% | 10.87% |
PSQH | 0.10% | $167.01M | -23.48% | 0.00% |
ASC | -0.13% | $561.10M | -10.90% | 7.85% |
KNOP | -0.13% | $207.33M | +1.33% | 1.72% |
NOC | 0.24% | $66.83B | -4.65% | 1.75% |
DAO | 0.24% | $204.25M | +74.40% | 0.00% |
BF.B | 0.27% | $16.00B | -39.30% | 2.59% |
CPSH | 0.35% | $25.56M | -23.48% | 0.00% |
SBUX | 0.48% | $104.59B | +0.29% | 2.51% |
OCFT | 0.54% | $93.46M | -12.11% | 0.00% |
GIS | 0.58% | $32.25B | -7.71% | 4.05% |
BVN | 0.59% | $3.22B | -13.84% | 0.00% |
EZPW | 0.61% | $643.78M | +38.41% | 0.00% |
MSB | -0.63% | $349.65M | +27.27% | 5.08% |
TCTM | -0.64% | $6.23M | -37.75% | 0.00% |
TSN | 0.66% | $18.95B | -1.09% | 3.58% |
SAN | -0.72% | $68.63B | +12.14% | 4.58% |
Yahoo
WATERTOWN, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines with biologics-like activity for immunological diseases, today announced that the Company will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, California on Tuesday, January 14, 2025, at 9:00 a.m. PT/12:00 p.m. ET. Nello Mainolfi, PhD, Founder, President and CEO, will
Yahoo
Leerink keeps an Outperform rating and a $60 price target on Kymera Therapeutics (KYMR) while noting that the firm sees a “positive readthrough” from the J&J’s (JNJ) in-licensing of an oral STAT6 program from Kaken Pharmaceutical. Kymera has recently started a Phase 1 for STAT6 degrader KT-621, while JNJ announced an in-licensing deal with Japan-based Kaken Pharmaceutical for small molecule STAT6 program KP-723, and while there are limited data publicly available about KP-723, the deal serves as
SeekingAlpha
Explore Baker Brothers' biotech-focused 13F portfolio, with notable stake increases in Incyte, Summit Therapeutics, and other small-cap firms. Read more here.
SeekingAlpha
Kymera Therapeutics is a biotech company with promising candidates in its pipeline for inflammatory disorders. Read why KYMR stock is a Strong Buy.
Yahoo
WATERTOWN, Mass., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the Company will participate in fireside chats at the following upcoming investor events: Piper Sandler 36th Annual Healthcare Conference in New York, NY on December 3 at 1:00 p.m. ET; and7th Annual Evercore ISI HealthCONx Conference in Coral Gables,
Yahoo
WATERTOWN, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the Company will participate in fireside chats at the following upcoming investor events: Guggenheim Inaugural Healthcare Innovation Conference in Boston, MA on November 12 at 10:00 a.m. ET;J.P. Morgan Equity Opportunities Forum in Miami, FL on Novem
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
HUSA | -15.29% | $21.99M | -1.18% | 0.00% |
PRPO | -12.06% | $9.09M | +14.66% | 0.00% |
HELE | -11.56% | $1.42B | -48.96% | 0.00% |
CBOE | -9.64% | $19.99B | +5.68% | 1.23% |
K | -9.52% | $28.10B | +47.08% | 2.77% |
STG | -9.52% | $28.83M | -36.52% | 0.00% |
TEN | -7.86% | $565.92M | -21.49% | 7.49% |
CYCN | -7.11% | $8.92M | -9.86% | 0.00% |
PULM | -6.79% | $21.95M | +206.95% | 0.00% |
FENG | -5.68% | $13.37M | +68.28% | 0.00% |
TTE | -5.64% | $129.26B | -14.55% | 5.90% |
SYPR | -5.60% | $49.73M | +2.37% | 0.00% |
VIRT | -4.38% | $2.98B | +81.55% | 2.80% |
DHT | -4.38% | $1.73B | -2.28% | 9.17% |
KDP | -4.31% | $41.21B | -4.79% | 2.92% |
BP | -4.22% | $82.51B | -10.24% | 5.89% |
MCK | -3.64% | $73.85B | +19.87% | 0.46% |
BTCT | -3.55% | $20.70M | -28.47% | 0.00% |
VHC | -3.11% | $28.01M | +19.97% | 0.00% |
ARLP | -2.94% | $3.48B | +22.64% | 10.31% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
XBI | 61.18% | $6.43B | 0.35% |
RSPA | 58.76% | $270.45M | 0% |
ARKG | 56.76% | $1.14B | 0.75% |
IBB | 56.60% | $6.45B | 0.45% |
GNOM | 56.32% | $71.69M | 0.5% |
PTH | 55.39% | $122.11M | 0.6% |
IWC | 55.37% | $960.03M | 0.6% |
IWO | 53.53% | $12.80B | 0.24% |
XPH | 53.22% | $158.66M | 0.35% |
VTWO | 52.09% | $12.36B | 0.1% |
KOMP | 51.95% | $2.11B | 0.2% |
IWM | 51.91% | $71.90B | 0.19% |
PBE | 51.51% | $254.47M | 0.58% |
ISCG | 51.04% | $642.78M | 0.06% |
VBK | 50.69% | $19.70B | 0.07% |
VXF | 50.13% | $21.54B | 0.06% |
SMMD | 49.69% | $1.37B | 0.15% |
NUSC | 49.61% | $1.23B | 0.31% |
PINK | 49.34% | $143.56M | 0.5% |
ESML | 49.23% | $1.89B | 0.17% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
KCCA | 0.18% | $116.13M | 0.87% |
CCOR | 0.20% | $83.85M | 1.18% |
SOYB | 0.22% | $24.83M | 0.22% |
FTGC | -0.55% | $2.25B | 1.02% |
DBC | -0.89% | $1.30B | 0.87% |
AGZD | -0.96% | $142.77M | 0.23% |
CLOI | 1.15% | $792.86M | 0.4% |
VRIG | 1.18% | $1.13B | 0.3% |
PDBC | -1.55% | $4.15B | 0.59% |
CORN | -1.69% | $63.58M | 0.2% |
GSG | -1.74% | $1.02B | 0.75% |
MEAR | 1.95% | $772.54M | 0.25% |
BILZ | -2.00% | $614.54M | 0.14% |
COMT | -2.17% | $688.84M | 0.48% |
KRBN | 2.23% | $194.27M | 0.85% |
BCI | 2.35% | $1.31B | 0.26% |
XHLF | -2.36% | $939.87M | 0.03% |
FLTR | 2.71% | $1.95B | 0.14% |
CANE | 3.18% | $12.08M | 0.29% |
DBO | -3.27% | $214.31M | 0.77% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
VIXY | -34.67% | $195.31M | 0.85% |
TAIL | -23.02% | $65.56M | 0.59% |
CTA | -18.92% | $497.20M | 0.76% |
TPMN | -14.51% | $41.63M | 0.65% |
USDU | -13.87% | $381.18M | 0.5% |
UUP | -12.01% | $607.07M | 0.77% |
UNG | -8.46% | $790.37M | 1.06% |
WEAT | -8.12% | $119.67M | 0.28% |
DBE | -6.24% | $48.12M | 0.77% |
DBA | -5.00% | $790.77M | 0.93% |
USCI | -4.79% | $193.45M | 1.07% |
DBO | -3.27% | $214.31M | 0.77% |
XHLF | -2.36% | $939.87M | 0.03% |
COMT | -2.17% | $688.84M | 0.48% |
BILZ | -2.00% | $614.54M | 0.14% |
GSG | -1.74% | $1.02B | 0.75% |
CORN | -1.69% | $63.58M | 0.2% |
PDBC | -1.55% | $4.15B | 0.59% |
AGZD | -0.96% | $142.77M | 0.23% |
DBC | -0.89% | $1.30B | 0.87% |